High SVR Rates with 8 and 12 Weeks of Pangenotypic Glecaprevir/Pibrentasvir: Integrated Efficacy and Safety Analysis of Genotype 1-6 Patients without Cirrhosis
Authors
Puoti, M; Foster, G; Wang, S; Mutimer, D; Gane, E; Moreno, C; Chang, TT; Lee, S; Marinho, R; Dufour, JCollections
- Centre for Immunobiology [1121]